Xia CHEN. Lessons Learnt from 5 Cases of Neurological Adverse Events and Death Occurring in the Clinical Trial of BIA 10-2474[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(3): 256-260. doi: 10.3969/j.issn.1674-9081.2018.03.013
Citation: Xia CHEN. Lessons Learnt from 5 Cases of Neurological Adverse Events and Death Occurring in the Clinical Trial of BIA 10-2474[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(3): 256-260. doi: 10.3969/j.issn.1674-9081.2018.03.013

Lessons Learnt from 5 Cases of Neurological Adverse Events and Death Occurring in the Clinical Trial of BIA 10-2474

doi: 10.3969/j.issn.1674-9081.2018.03.013
More Information
  • Author Bio:

    Tel: 010-67098888, E-mail:connie_6096@126.com

  • Received Date: 2017-09-04
  • Publish Date: 2018-05-30
  • In January 2016, a healthy subject in the Phase Ⅰ clinical trial of BIA 10-2474 in France experienced brain death after administration of the studied medicine. In order to explore the cause of this event and systematically mitigate the risk of early-phase clinical trials, this article sorted out the potential reasons in terms of the mechanism of drug effect, preclinical findings, design and execution of the clinical study based on the report written by the Temporary Specialist Scientific Committee involved in the survey of the BIA 10-2474 study. The lessons learnt from this tragedy may include:(1)the decision on clinical development should be made carefully according to available research data and relevant information obtained from similar drugs, so as to improve the rate of success and avoid unnecessary risks; (2)the trial design should consider safety findings and pharmacody-namic properties of the drug in pre-clinical studies, as well as the scientific objectives of the study; (3)in early-stage clinical trials of novel drugs, investigators should be fully aware of the potential risks, even small signals should be noted. Whenever there is an emerging event, it is recommended to perform a comprehensive analysis on the event and then treat it conservatively.
  • loading
  • [1] Kaur R, Sidhu P, Singh S. What failed BIA 10-2474 Phase I clinical trial? Global speculations and recommendations for future Phase I trials[J]. J Pharmacol Pharmacother, 2016, 7:120-126. doi:  10.4103/0976-500X.189661
    [2] Zarafonetis CJ, Riley PA Jr, Willis PW 3rd, et al. Clinically significant adverse effects in a Phase 1 testing program[J]. Clin Pharmacol Ther, 1978, 24:127-132. doi:  10.1002/cpt1978242127
    [3] Sibille M, Deigat N, Olagnier V, et al. Adverse events in phase one studies:a study in 430 healthy volunteers[J]. Eur J Clin Pharmacol, 1992, 42:389-393. doi:  10.1007/BF00280124
    [4] Lutfullin A, Kuhlmann J, Wensing G. Adverse events in volunteers participating in phase I clinical trials:a single-center five-year survey in 1, 559 subjects[J]. Int J Clin Pharmacol Ther, 2005, 43:217-226. doi:  10.5414/CPP43217
    [5] Johnson RA, Rid A, Emanuel E, et al. Risks of phase I research with healthy participants:A systematic review[J]. Clin Trials, 2016, 13:149-160. doi:  10.1177/1740774515602868
    [6] Kenter MJ, Cohen AF. Establishing risk of human experimentation with drugs:lessons from TGN1412[J]. Lancet, 2006, 368:1387-1391. doi:  10.1016/S0140-6736(06)69562-7
    [7] Guideline on strategy to identify and mitigate risks for first-in-human clinical trials with investigational medical products[EB/OL].http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2017/07/WC500232186.pdf.
    [8] Tranter E, Peters G, Boyce M, et al. Giving monoclonal antibodies to healthy volunteers in phase 1 trials:is it safe?[J]. Br J Clin Pharmacol, 2013, 76:164-172. doi:  10.1111/bcp.12096
    [9] Hackam DG, Redelmeier DA. Translation of research evid-ence from animals to humans[J]. JAMA, 2006, 296:1731-1732. http://med.wanfangdata.com.cn/Paper/Detail/PeriodicalPaper_PM17032985
    [10] Whitebread S, Dumotier B, Armstrong D, et al.Secondary pharmacology:screening and interpretation of off-target activities-focus on translation[J]. Drug Discov Today, 2016, 21:1232-1242. doi:  10.1016/j.drudis.2016.04.021
    [11] Ahuja V, Sharma S.Drug safety testing paradigm, current progress and future challenges:an overview[J]. J Appl Toxicol, 2014, 34:576-594. doi:  10.1002/jat.2935
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)

    Article Metrics

    Article views (344) PDF downloads(151) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return